Curcumin loaded deformable drug carrier for the disease of posterior segment of eye: diabetic retinopathy

Priti Singh and Dr. Vandana Gupta

DOI: https://doi.org/10.22271/tpi.2020.v9.i12d.5442

Abstract
Diabetic Retinopathy (DR) is one of the most common complications of diabetes mellitus that affects the blood vessels of the retina, leading to blindness. The current approach of treatment based on anti-inflammatory, anti-angiogenesis drugs and laser photocoagulation are effective but also shows adverse affect in retinal tissues and that can even worsen the visual abilities. Thus, a safe and effective mode of treatment is needed to control or delaying the DR. Based on the earlier evidence of the potentiality of natural products as anti-oxidants, anti-diabetic and antitumor, medicinal plants may constitute a good therapeutic approach in the prevention and treatment of DR. Curcumin, constituents of dietary spice turmeric, has been observed to have therapeutic potential in the inhibition or slow down progression of DR. In this review, we summarize the therapeutic potentiality of curcumin in the delaying the DR through antioxidant, anti-inflammatory, inhibition of Vascular Endothelial Growth and nuclear transcription factors. In period of time. Curcumin, the major extract of termuric, has been widely used in many countries for centuries both as a medicine. In the last decade, researchers have found the beneficial effects of curcumin on multiple disorders are due to its antioxidant, anti-inflammatory, and antiproliferative properties, as well as its novel function as an inhibitor of histone acetyltransferases. In this review, we summarize the recent progress made on studying the beneficial effect of curcumin on multiple retinal diseases, including diabetic retinopathy, glaucoma, and age-related macular degeneration. Recent clinical trials on the effectiveness of phosphatidylcholine formulated curcumin in treating eye diseases have also shown promising results, making curcumin a potent therapeutic drug candidate for inflammatory and degenerative retinal and eye diseases. Posterior segment diseases, including age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema (DME), retinal vein occlusion (RVO), uveitis, and endophthalmitis, are responsible for causing visual impairment and blindness worldwide. The purpose of this study was to evaluate the therapeutic potential of ophthalmic curcumin in the prevention and treatment of posterior segment of eye.

Keywords: Curcumin, Transfersome, topical drug delivery

Introduction
Materials and Methods
Materials - Chloroform, di-potassium hydrogen phosphate, potassium dihydrogen orthophosphate and sodium hydroxide pellets (AR grade) were procured from S.D. Fine Chemicals Ltd. (Mumbai, India). Rhodamine Red-X (RR) was obtained from Molecular Probe (Eugene, OR). Florida cream 5% w/w as marketed formulation (marketed product) was purchased from local medical shop. Span-60, Span-80 and Tween-80 were purchased from Himedia (Mumbai, India). HPLC grade methanol and water were procured from Sigma-Aldrich (Mumbai, India). Ethanol and acetone were obtained from Avarice Laboratories Pvt., Ltd. Dialysis membrane with molecular weight cut off value of 12 000–14 000 Dalton was procured from Himedia. In this study, all other reagents were of analytical grade. Double distilled water and Milli-Q water (Millipore, Bedford, MA) were used throughout the experiments.

Methods / Preparation of Transfersome
The transfer some were prepared by modified hand shaking, lipid film hydration technique. The composition of Drug (curcumin), polymer (lecithin) (PC) and edge activator (tween-80, span-80) were dissolved in ethanol: chloroform (1:1) mixture in a round bottom flask. Organic solvent was removed by rotary film evaporator under reduced pressure at 60 °C ± 2 °C and 60
rpm to get a homogeneous lipid film. A thin lipid film was formed inside the flask wall with rotation. The thin film was kept overnight for complete evaporation of solvent. The film was then hydrated with phosphate buffer (pH 7.4) with gentle shaking for 15 minute at corresponding temperature. The transfersome suspension further hydrated up to 1 hour at 2-8°C to obtained multilamellar (MLVs). The resulting MLVs were kept overnight at 4 °C to allow the complete hydration of the vesicles. The MLVs were then subjected to probe sonication at 4 °C for 2 min using ultrasonic sonicator to get small unilamellar vesicles (SUVs). The SUVs were then passed 10 times through 0.45 and 0.20 µm hydrophilic syringe filters to get uniform sized nanovesicles which were kept at 4 °C for further characterization. A similar methodology was used for the preparing blank transfersomes without curcumin. Similarly, CUR loaded liposome formulations were also prepared using lacithine and surfactant in 85:15 ratio that was used as a control formulation for in vitro release study experiments.

Results and Discussion

- Preformulation studies
- Test for identification of the drug

Physical appearance: The organoleptic properties like general appearance etc. were performed by visual observation. A small quantity of drug was taken on butter paper and viewed in well-illuminated place. The taken curcumin sample is a Orange-yellow crystalline powder.

| Table 1: Description of Organoleptic properties of drug |
|-----------------|-----------------|-----------------|
| Drug            | Test            | Observation     |
| Curcumin        | Color           | Orange powder   |
| Curcumin        | Taste           | Acrid           |
| Curcumin        | Odour           | Odorless        |

Melting point - The melting point of sample of curcumin was determined as per procedure given in materials and methods part. The performed melting point were 180°C.

| Table 2: Melting point of Curcumin |
|-----------------|-----------------|-----------------|
| Drug            | Apparatus       | Specification   | Result    |
| Curcumin        | Vegus           | 179-185°C       | 184-185°C |

Solubility- Solubility study of Curcumin was performed using shaking method in different vehicles and the observed results were solubility in water 0.012±0.012, in acetone 20±0.231, in ethanol 10±0.121. The drug was observed to be having very low solubility in water and showed good solubility respectively in remaining four solutions. Such measure confirmed the poorly aqueous soluble nature of Curcumin.

| Table 3: Solubility of Curcumin in various solvents |
|-----------------|-----------------|-----------------|
| S/no. | Drug            | Vehicles       | Solubility mg/ml |
|---|-----------------|-----------------|-----------------|
| 1 | Curcumin        | Water           | 0.012±0.012     |
| 2 | Curcumin        | Acetone         | 20±0.231        |
| 3 | Curcumin        | Ethanol         | 10±0.129        |
| 4 | Curcumin        | Dichloromethane | 05±0.327        |
| 5 | Curcumin        | PBS 7.4         | 0.081±0.014     |

Standard curve- The standard curve was obtained by plotting data of absorbance v/s concentration (µg/ml).

| Table 4: Absorbance values for standard calibration curve in ethanol |
|-----------------|-----------------|-----------------|
| Concentration in µg/ml | Absorption at λ.max 412 nm |
| 2               | 0.178           |
| 4               | 0.395           |
| 6               | 0.617           |
| 8               | 0.768           |
| 10              | 0.984           |
| 12              | 1.112           |

Calibration curve of Curcumin in Acetone

![Fig 1: Standard curve of curcumin in acetone](image)

Drug excipients interaction: FTIR analysis measures the selective absorption of light by the vibration modes of specific Chemical bonds in the sample. The Observation of vibration spectrum of Curcumin, different Excipients, physical mixtures allows evaluating the kind of interaction Occurring between the drug and polymer, because the vibration of atoms involved in this Interaction can suffer alteration in frequency and intensity. FTIR analysis was conducted to verify the occurrence of chemical bonds between drug and excipients. Figure shows the FTIR Spectrum of Curcumin PLGA and physical mixtures. The spectral analysis indicates that the specific functional group of the Curcumin and physical mixture has almost the same characteristics as that of pure drug and polymer combinations. The study suggests that molecular interactions did not occur that could alter the chemical structure of Curcumin. Hence the chemical structure is likely to be unaffected during physical mixture and due to the low content of drug in the formulation, its detection would have been difficult in the
FTIR experiments and the characteristics band of Curcumin would have been masked by the polymer absorptive band at the same position, which therefore would conceal any possible interactions such as hydrogen bonding.

**Table 5:** Peak and chemical group present in IR spectrum of Physical mixture

| Frequency in (cm⁻¹) | Functional group     |
|---------------------|----------------------|
| 3309.85             | O-H Stretching       |
| 2883.58             | C=C-H Stretching     |
| 2237.43             | C≡N Stretching       |
| 1959.68             | C=O Stretching       |
| 1734.01             | C=O Stretching       |
| 1627.92             | C≡C Stretching       |

**Interpretation**
The spectrum of drug sample is shown in fig. The interpretation of FTIR of Curcumin is summarized in table. All the peaks given in the table and their functional groups present in the molecular structure of the Curcumin is shown figure. On the basis of spectra we could sure the sample is pure Curcumin drug.

**Table 6:** Optimization of done selecting entrapment efficiency of drug

| Edge activators | Formulation code | LEC:TS | solvent       |
|-----------------|------------------|--------|---------------|
| Tween-80        | A                | 95:05  | Ethanol       |
|                 | B                | 85:15  |               |
|                 | C                | 95:05  | Isopropyl alcohol |
|                 | D                | 85:15  |               |
| Span-80         | E                | 95:05  | Ethanol       |
|                 | F                | 85:15  |               |
|                 | G                | 95:05  | Isopropyl alcohol |
|                 | H                | 85:15  |               |

LEC-indicate lecithine, TS- indicate Tween-80 and Span-80

**Optimization of transferosomes**
There are various process variables which could affect the preparation and properties of the transfersomes. The preparation procedure was accordingly optimized and validated. The preparation of transfersomes containing curcumin involves various process variables such as effect of lecithin: surfactant ratio (95:05,85:15), effect of various solvents (ethanol, isopropyl alcohol) and effect of various surfactants (Span80, Tween80), optimization was done by selecting entrapment efficiency of drug. During the preparation of a particular system, the other variables were kept constant.

**Morphological analysis of vehicles**

**Entrapment efficiency**
The values obtained after UV-visible spectroscopy are fitted in formula and results are obtained are: - % EE =entrapped
drug / total drug taken \( \times 100 \)

| Table 7: Determination of Entrapment efficiency of percentage |
|---------------------------------|-----------------|------------------|
| **Molar ratio (LEC:TS)** | **Formulation code** | **%EE**          |
|---------------------------------|-----------------|------------------|
| **Tween-80** |                 |                 |
| 95:05                            | A               | 69.2±0.065       |
| 85:15                            | B               | 74.6±0.031       |
| 95:05                            | C               | 75.3±0.028       |
| 85:15                            | D               | 78.3±0.076       |
| **Span-80**                      |                 |                 |
| 95:05                            | E               | 72.6±0.044       |
| 85:15                            | F               | 79.0±0.035       |
| 95:05                            | G               | 83.7±0.022       |
| 85:15                            | H               | 88.6 ±0.055      |

In Vitro Release Study: Membrane-free Model - The cumulative amount of drug released after 24 h in case of EV dispersion and EVs incorporated into the hydrophilic ointment base was found to be 1320.62 ± 34.86 and 1085.38 ± 36.28 \( \mu \)g, respectively. Both the systems showed first-order release kinetics (r \( \geq 0.9826 \)) and 0.9759, respectively; Fig. 6. Curcumin is known to be soluble (17.75 ± 0.11 mg/mL) in Labrafac CC (32).

Discussion

- Curcumin drug was selected as a suitable drug candidate for this study because it is very bitter in taste. Thus, taste masking is very important for administration in patients mainly diabetic.
- Transfersome were prepared by Hand shaking method as it is a cheap, fast method and desired particle size range is achieved. It synthesis was preferred for the formulation of Transfersome because of the reported hazards of adding organic solvent. Thus 0.1 N HCl used as solvent for dissolving drug and polymer. 0.1 N NaOH was used as antisolvent.
- Characterization of Transfersome was done on the basis of taste masking, size and shape, entrapment efficiency, DSC.
- Topical delivery was performed on human volunteers. Based on their responses, it was evident that the prepared Transfersome absorb in posterior segment of eye Size of were found uniform by optically microscopy. Entrapment efficiency was found to be 78% (85:15) and 88% (85:15).
- Transfersome was formulated due to several advantage.

Three polymers were used i.e. Lecithin (1%, 0.5%, 2%), Tween 80 (1%, 0.5%, 2%), Span 80 (1%, 0.5%, 2%).
- Prepared Transfersome was characterized on the basis of parameters like sedimentation volume, degree of redisperisibility, flow rate, viscosity. From the results, it was evident that Transfersome containing Span 80 (0.5%) was showing best results among all four formulations.
- From the stability study results it was found that the selected formulation H was found to be stable. There was no significant change from initial readings to final results after 1 month of stability studies.
- Topical evaluation was performed on human volunteers. Based on their responses, prepared Transfersome was found to be absorbed in posterior segment of eye was successfully done.
- The DSC curve showed the sharp peak at the respective melting point of Curcumin The melting point of curcumin was found to be 100-150°C. DSC curve of Curcumin show its peak at its reported melting point of 150 °C. Figure 8 shows DSC curve of pure Curcumin. The result of DSC analysis also confirm that drug sample obtained were pure and could be used for further work.
- The DSC curve of Transfersome entrapped with curcumin also showed the peak at respective melting point of Curcumin. The melting point of Transfersome containing curcumin was found to be between 100-150°C. The result of DSC analysis also confirm that drug sample obtained contained entrapped Curcumin. The result also shows that the broad peak of Transfersome entrapped curcumin was due to the transformation of crystalline phase to amorphous phase. This transformation was due to the incorporation of drug inside Curcumin.

References

1. Patel SS, Patel MS et al. Development and evaluation of liposomes for topical delivery of tacrolimus (FK-506) J Sci Res 2010;2(3):585-596.
2. Achim M, Precup C et al. Thermosensitive liposomes containing doxorubicin. Preparation and in vitro evaluation Farmacia 2009;57(6):703-710.
3. Aukunuru J, Joginapally S et al. Preparation, characterization and evaluation of hepatoprotective activity of an intravenous liposomal formulation of bin-demethoxy curcumin analogue (BDMCA) Int J Drug Dev & Res 2009;1(1):37-46.
4. Bhatia A. Tamoxifen in topical liposomes: development, characterization and in vitro evaluation J Pharm Pharmacuet Sci 2004;7(2):252-259.
5. Sanborn GE, Anand R, Torti RE. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Arch Ophthalmol 1992;110:188-195.
6. Olsen TW, Aaberg SY, Geroski DH, Edelhauser HF. Human sclera: thickness and surface area. Am J Ophthalmol 1998;125:237-241.
7. Bill A. Movement of albumin and dextran through the sclera. Arch Ophthalmol 1965;74:248-252.
8. Barza M, Kane A, Baume JL. Intraocular penetration of gentamicin after subconjunctival and retrobulbar injection. Am J Ophthalmol 1978;85:541-547.
9. Barza M, Kane A, Baume JL. Regional differences in ocular concentration of gentamicin after subconjunctival and retrobulbar injection in the rabbit. Am J Ophthalmol
10. Wine NA, Gornall AG, Basu PK. The ocular uptake of subconjunctivally injected C14 hydrocortisone. Am J Ophthalmol 1964;58:362-366.
11. Kokate A et al. Physiological and biochemical barriers to drug delivery. In: Li X, Jasti BR, eds. Design of Controlled Release Drug Delivery Systems. New York, NY: McGraw-Hill 2006, 41-73.
12. Ravivarapu H et al. Biodegradable polymeric delivery systems. In: Li X, Jasti BR, eds. Design of Controlled Release Drug Delivery Systems. New York, NY: McGraw-Hill 2006, 271-303.
13. Yasukawa T, Ogura Y, Tabata Y et al. Drug delivery systems for vitreoretinal diseases. Prog Retina Eye Res 2004;23(3):253-281.
14. Lee VH, Robinson JR. Topical ocular drug delivery: recent developments and future challenges J Ocul Pharmacol 1986;2(1):67-108.
15. Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev 2005;57(14):2010-2032.
16. Idrees F, Vaideanu D, Fraser SG et al. A review of anterior segment dysgeneses. Surv Ophthalmol 2006;51(3):213-231.
17. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci 2000;41(5):961-964.
18. Ahmed I, Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci 1985;26(4):584-547.
19. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today 2008;13(3-4):144-151.
20. Loftsson T, Järvinen T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev 1999;36(1):59-79.